TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26137324

Group type: EXPERIMENTAL
Intervention: Lithium (n = 23, 0.79 ± 0.15 mEq/L)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Valproate (n = 13, 79.6 ± 12.4 mg/mL)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Comparison between Lithium and Valproate
Number of subjects: 36
Study: 23362326

Group type: EXPERIMENTAL
Intervention: Plasma miRNA profiling using reverse transcriptase quantitative PCR (RT-qPCR)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Plasma miRNA profiling
Number of subjects: 88
Study: 21240457

Group type: EXPERIMENTAL
Intervention: nanoparticle albumin-bound paclitaxel (nab-paclitaxel)
Number of subjects: 43

Group type: COMPARATOR
Intervention: doxorubicin
Number of subjects: 43

Group type: COMPARATOR
Intervention: paclitaxel
Number of subjects: 43

Group type: COMPARATOR
Intervention: docetaxel
Number of subjects: 43
Study: 19595444

Group type: EXPERIMENTAL
Intervention: Beautifil Flow F02 at 2.5 mm marginal ridge height
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Various restorative materials (Ketac Aplicap, Fuji IX, Fuji II LC, Beautifil Flow F02)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Remaining marginal ridge height
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (sound teeth)
Number of subjects: 120
Study: 17205445

Group type: EXPERIMENTAL
Intervention: E-test antibiotic strips (AB Biodisk) applied directly on respiratory tract samples
Number of subjects: 0
Study: 15518296

Group type: EXPERIMENTAL
Intervention: Sprint training (n=8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (n=8)
Number of subjects: 16
Study: 10891925

Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (mCPP) 0.5 mg/kg
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 8808107

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and corticosteroids
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Corticosteroids and cyclophosphamide
Number of subjects: 107
Study: 1364953

Group type: EXPERIMENTAL
Intervention: Cyclo‐cryocoagulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trans‐scleral panretinal cryocoagulation in combination with cyclo‐cryocoagulation
Number of subjects: 0
Study: 3843217

Group type: EXPERIMENTAL
Intervention: Clobazam (15 to 60 mg per day)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Clobazam (dose changes)
Number of subjects: 14
Study: 3492260

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (Intron A) high dose (50 X 10(6) IU/m2 intravenously)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (Intron A) intermediate dose (30 X 10(6) IU/m2 subcutaneously)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (Intron A) low dose (1 X 10(6) IU/m2 subcutaneously)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (Intron A) high dose
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (Intron A)
Number of subjects: 114
Study: 31585766

Group type: EXPERIMENTAL
Intervention: Point-of-Care Ultrasound (POCUS)
Number of subjects: 469
Study: 29140136

Group type: EXPERIMENTAL
Intervention: Salt-induced hyperhydration (SIH)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Glycerol-induced hyperhydration (GIH)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Salt + Glycerol-induced hyperhydration (SGIH)
Number of subjects: 15
Study: 26935859

Group type: EXPERIMENTAL
Intervention: Early ACL reconstruction (n=62, within 10 weeks of injury)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Optional delayed ACL reconstruction (n=59; 30 with ACL reconstruction within 6-55 months)
Number of subjects: 121
Study: 25549549

Group type: EXPERIMENTAL
Intervention: Camel Snus
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Sticks
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Strips
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Orbs
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Controlled Dual use (DU) of cigarettes and Camel Snus
Number of subjects: 167

Group type: COMPARATOR
Intervention: Tobacco abstinence
Number of subjects: 167
Study: 23279371

Group type: EXPERIMENTAL
Intervention: Bilateral superficial cervical plexus block with 15 mL of 0.25% bupivacaine (group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bilateral superficial cervical plexus block with 0.25% bupivacaine and 1 μg/kg clonidine (group BC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% normal saline (group S)
Number of subjects: 60
Study: 20122367

Group type: EXPERIMENTAL
Intervention: Ondansetron 16 mg per day for 10 weeks
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo for 10 weeks
Number of subjects: 67
Study: 18004687

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (SB: NaHCO3 300 mg . kg (‐1) body mass)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (P: CaCO3 200 mg . kg (‐1) body mass)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (SB)
Number of subjects: 9
Study: 16841201

Group type: EXPERIMENTAL
Intervention: Immobilization for 6-8 weeks
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Reloading (3-5 days after immobilization)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Rehabilitation (10 weeks)
Number of subjects: 8
Study: 14557359

Group type: EXPERIMENTAL
Intervention: Adenosine BOLD-MRI
Number of subjects: 25

Group type: COMPARATOR
Intervention: Adenosine thallium SPECT
Number of subjects: 25
Study: 11094666

Group type: EXPERIMENTAL
Intervention: ropivacaine 0.125% with fentanyl 2 micrograms/ml
Number of subjects: 36

Group type: COMPARATOR
Intervention: ropivacaine 0.125%
Number of subjects: 36
Study: 8883031

Group type: EXPERIMENTAL
Intervention: Antacid, ranitidine, and misoprostol (prostaglandin E1)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Antacid and ranitidine
Number of subjects: 87

Group type: COMPARATOR
Intervention: Antacid, ranitidine, and bismuth (De Nol)
Number of subjects: 87
Study: 1383590

Group type: EXPERIMENTAL
Intervention: Mexicord (antiarrhythmic agent)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ethmozine (control)
Number of subjects: 0
Study: 2864634

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 1884

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1884
Study: 29715553

Group type: EXPERIMENTAL
Intervention: Baseline model (preoperative period)
Number of subjects: 3569

Group type: EXPERIMENTAL
Intervention: Perioperative model
Number of subjects: 3569

Group type: EXPERIMENTAL
Intervention: At-discharge model
Number of subjects: 3569

Group type: EXPERIMENTAL
Intervention: All models with score ≥8 points
Number of subjects: 3569
Study: 30047579

Group type: EXPERIMENTAL
Intervention: Football training group (FTG; n = 27, 14 women)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (CON; n = 23, 11 women)
Number of subjects: 50
Study: 26895345

Group type: EXPERIMENTAL
Intervention: Cu-IUD
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: LNG-IUS
Number of subjects: 703
Study: 24709166

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 77

Group type: COMPARATOR
Intervention: Levofloxacin plus Metronidazole
Number of subjects: 77
Study: 23385630

Group type: EXPERIMENTAL
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ranibizumab (0.5 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pegaptanib (0.3 mg)
Number of subjects: 60
Study: 21467832

Group type: EXPERIMENTAL
Intervention: Sevoflurane (group T-S)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Propofol (group T-P)
Number of subjects: 130
Study: 17184783

Group type: COMPARATOR
Intervention: Brief advice alone
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Individual nurse support
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Group support facilitated by nurses
Number of subjects: 91
Study: 17164742

Group type: EXPERIMENTAL
Intervention: ranolazine 1000 mg b.i.d. (n=22)
Number of subjects: 45

Group type: COMPARATOR
Intervention: placebo (n=23)
Number of subjects: 45
Study: 12792657

Group type: EXPERIMENTAL
Intervention: Myristic acid meal (M)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Stearic acid meal (S)
Number of subjects: 10
Study: 11148849

Group type: EXPERIMENTAL
Intervention: Bilateral ovarian drilling by minilaparoscopy under local anesthesia (Group A)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Bilateral ovarian drilling by traditional laparoscopy under general anesthesia (Group B)
Number of subjects: 62
Study: 8682263

Group type: EXPERIMENTAL
Intervention: Bidirectional Filter (BF) - 340 Patients
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Spectral Filter (SF) - 258 Patients
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Del Mar Filter (DF) - 49 Patients
Number of subjects: 647

Group type: COMPARATOR
Intervention: Comparison of all filters
Number of subjects: 647
Study: 1570975

Group type: EXPERIMENTAL
Intervention: Bubble oxygenator without an arterial line filter (n = 9)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Bubble oxygenator with a depth adsorption filter (n = 10)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Flat-sheet membrane oxygenator without a filter (n = 10)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Preoperative MRI findings
Number of subjects: 29
Study: 3898298

Group type: EXPERIMENTAL
Intervention: Thymopentin (50 mg, intravenous injections, 3 times a week for 3 consecutive weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Thymopentin
Number of subjects: 41
Study: 31277111

Group type: EXPERIMENTAL
Intervention: Minimally invasive periodontal surgery
Number of subjects: 33

Group type: COMPARATOR
Intervention: Traditional surgery
Number of subjects: 33
Study: 29077992

Group type: EXPERIMENTAL
Intervention: Exendin‐(9‐39) at a maximum recommended starting dose of 27 mg kg‐1 day‐1 intravenously
Number of subjects: 26

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 26
Study: 27003305

Group type: EXPERIMENTAL
Intervention: Cholecystokinin (CCK)‐8 induced gallbladder emptying
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of CCK and Metformin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CCK-induced gallbladder emptying
Number of subjects: 10

Group type: COMPARATOR
Intervention: Metformin alone
Number of subjects: 10
Study: 23760362

Group type: EXPERIMENTAL
Intervention: Strength training (N = 14)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (N = 5)
Number of subjects: 19
Study: 22287353

Group type: EXPERIMENTAL
Intervention: FOLFOX4 as conventional neoadjuvant chemotherapy (Group A)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: FOLFOX4 plus bevacizumab (Group B)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy delivered 5 days after bevacizumab treatment according to NWTV (Group C)
Number of subjects: 93
Study: 20735801

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 42
Study: 18519778

Group type: EXPERIMENTAL
Intervention: rhIL-18 administered as a 2-h i.v. infusion on 5 consecutive days repeated every 28 days (group A)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: rhIL-18 administered as a 2-h i.v. infusion once a week (group B)
Number of subjects: 19
Study: 15840878

Group type: EXPERIMENTAL
Intervention: Systematic pelvic and para-aortic lymphadenectomy
Number of subjects: 427

Group type: COMPARATOR
Intervention: Resection of bulky nodes only (Control)
Number of subjects: 427
Study: 12902099

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (n = 14)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (n = 7)
Number of subjects: 21
Study: 10480825

Group type: EXPERIMENTAL
Intervention: Educational and clinical practice audit programme for general practitioners on health promotion for elderly people
Number of subjects: 267

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 267
Study: 7496122

Group type: EXPERIMENTAL
Intervention: Polyspecific antiglobulin serum (83.2% with anti-IgG)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Tube test
Number of subjects: 97
Study: 1828543

Group type: EXPERIMENTAL
Intervention: Subcutaneous rHuEPO (84 ± 9 U/kg body weight/week)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intraperitoneal rHuEPO (133 ± 7 U/kg body weight/week)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intraperitoneal rHuEPO
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Patients who were hypertensive prior to rHuEPO therapy
Number of subjects: 20
Study: 7317896

Group type: EXPERIMENTAL
Intervention: Propranolol (360 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Smoking
Number of subjects: 10
Study: 31859096

Group type: EXPERIMENTAL
Intervention: Aromatherapy massage with lavender and chamomile oil
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo massage
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group (daily routine care)
Number of subjects: 105
Study: 30468803

Group type: EXPERIMENTAL
Intervention: Increasing the proportion of healthier foods available in worksite cafeterias
Number of subjects: 6
Study: 28400146

Group type: EXPERIMENTAL
Intervention: PHQ-9 with alternate cutpoint of 6
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: CES-D with traditional cutpoint of 16
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: CES-D with stringent cutpoint of 22
Number of subjects: 153
Study: 26189231

Group type: EXPERIMENTAL
Intervention: High-dose midazolam (MDZ) alone (G1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-dose MDZ and dexmedetomidine (DEX) (G2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-dose MDZ and DEX (G3)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-dose MDZ and high-dose DEX (G4)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-dose MDZ and low-dose DEX (G5)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: High-dose DEX alone (G6)
Number of subjects: 60
Study: 23737255

Group type: EXPERIMENTAL
Intervention: Chewing gum containing Lactobacillus reuteri (2 × 10^8 CFU per dose), twice daily for 12 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 23
Study: 20938783

Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg)
Number of subjects: 12
Study: 19225530

Group type: EXPERIMENTAL
Intervention: Telmisartan (80 mg)
Number of subjects: 1613

Group type: COMPARATOR
Intervention: Ramipril (5 or 10 mg)
Number of subjects: 1613
Study: 17014994

Group type: EXPERIMENTAL
Intervention: Intraoperative local anaesthetic (2% lidocaine with 1:200,000 epinephrine)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Saline intraoral injection
Number of subjects: 142
Study: 15259280

Group type: EXPERIMENTAL
Intervention: E2V/MPA triphasic
Number of subjects: 740

Group type: COMPARATOR
Intervention: E2V/MPA biphasic
Number of subjects: 740

Group type: COMPARATOR
Intervention: E2/NETA triphasic
Number of subjects: 740
Study: 11411890

Group type: EXPERIMENTAL
Intervention: Educational intervention delivered by a computer aided learning package
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (read radiographs twice, received no intervention)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Second group (read radiographs once after the intervention)
Number of subjects: 95
Study: 9431479

Group type: EXPERIMENTAL
Intervention: Plasma estradiol concentrations in premenopausal women with CHD
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Total estrogen concentrations in premenopausal women with CHD
Number of subjects: 14

Group type: COMPARATOR
Intervention: Plasma estradiol concentrations in healthy control group
Number of subjects: 14

Group type: COMPARATOR
Intervention: Total estrogen concentrations in healthy control group
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Progesterone concentrations in premenopausal women with CHD
Number of subjects: 14

Group type: COMPARATOR
Intervention: Progesterone concentrations in healthy control group
Number of subjects: 14
Study: 7634748

Group type: EXPERIMENTAL
Intervention: Z-coefficient method
Number of subjects: 11

Group type: COMPARATOR
Intervention: Cross-spectrum analysis
Number of subjects: 11
Study: 2793610

Group type: EXPERIMENTAL
Intervention: Repetitive identical tone bursts with infrequent shorter tones
Number of subjects: 0
Study: 702245

Group type: EXPERIMENTAL
Intervention: Early surgical closure protocol
Number of subjects: 15

Group type: COMPARATOR
Intervention: Medical management protocol
Number of subjects: 15
Study: 31272405

Group type: EXPERIMENTAL
Intervention: Median‐to‐ulnar nerve difference (MUD)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Median‐to‐ulnar nerve ratio (MUR)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Cross‐sectional area of the median nerve at the pisiform level (CSA‐P)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Swelling ratio (SR)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Receiver operator characteristic curve (ROC) for MUD
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Receiver operator characteristic curve (ROC) for MUR
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Receiver operator characteristic curve (ROC) for CSA‐P
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Receiver operator characteristic curve (ROC) for SR
Number of subjects: 64
Study: 27129584

Group type: EXPERIMENTAL
Intervention: Sintered bovine bone substitute material (SBM, Alpha Bio's Graft®)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Non-sintered bovine bone substitute material (NSBM, Bio Oss®)
Number of subjects: 33
Study: 26572698

Group type: EXPERIMENTAL
Intervention: Traffic noise exposure during 3 nights
Number of subjects: 10

Group type: COMPARATOR
Intervention: No traffic noise during 3 nights
Number of subjects: 10
Study: 25092108

Group type: EXPERIMENTAL
Intervention: L-carnitine (LC) 1000 mg/d
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 21775070

Group type: EXPERIMENTAL
Intervention: Capecitabine (1,200 mg/m(2)/d Mondays through Friday) and Irinotecan (50 mg/m(2) weekly in four doses) with concurrent radiotherapy (50.4 Gy in 1.8‐Gy fractions) (Arm 1)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Capecitabine (1,650 mg/m(2)/d Monday through Friday) and Oxaliplatin (50 mg/m(2) weekly in five doses) with concurrent radiotherapy (50.4 Gy in 1.8‐Gy fractions) (Arm 2)
Number of subjects: 146
Study: 19383889

Group type: EXPERIMENTAL
Intervention: 12‐week Better Exercise Adherence after Treatment for Cancer intervention
Number of subjects: 41
Study: 17616297

Group type: EXPERIMENTAL
Intervention: Tirofiban infusion followed by sirolimus-eluting stent (SES)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Abciximab plus bare-metal stent (BMS)
Number of subjects: 175
Study: 15135267

Group type: EXPERIMENTAL
Intervention: 1mg of 17 beta‐estradiol orally combined with 100 mg progesterone
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: 50 microg transdermally combined with 100 mg progesterone
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 11295627

Group type: EXPERIMENTAL
Intervention: Dietary and lifestyle intervention (low-fat, soy-supplemented vegan diet, stress management, psychosocial support, exercise programs)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (watchful waiting)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Dietary and lifestyle intervention
Number of subjects: 93
Study: 9133340

Group type: EXPERIMENTAL
Intervention: Sugar-coated tablet formulation (Femavit 1.25)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oral suspension
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both preparations
Number of subjects: 18
Study: 8188994

Group type: EXPERIMENTAL
Intervention: Gastrolyte (240 mosm/l)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Glucolyte (340 mOsm/l)
Number of subjects: 45
Study: 3532900

Group type: EXPERIMENTAL
Intervention: Ketanserine (80 mg/day for 6 months)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Ketanserine
Number of subjects: 27
Study: 29994756

Group type: EXPERIMENTAL
Intervention: Stochastic training of neural networks via successive convex approximations
Number of subjects: 0
Study: 26681725

Group type: EXPERIMENTAL
Intervention: Intranasal glucagon (3 mg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Intramuscular glucagon (1 mg)
Number of subjects: 75
Study: 25296655

Group type: EXPERIMENTAL
Intervention: Multidisciplinary Multistep Medication Review (3MR)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 600
Study: 21864869

Group type: EXPERIMENTAL
Intervention: High-intensity resistance exercise (RE)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 12
Study: 19841860

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZOL) 5 mg infusion
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 9
Study: 17650792

Group type: EXPERIMENTAL
Intervention: Biliary drainage via endoscope (ENBD) combined with Chinese drug medication (CTG)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Routine treatment with ENBD alone (RTG)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (CG) with simple gallbladder stone
Number of subjects: 16
Study: 15618250

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily for 3 months)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg for 3 months)
Number of subjects: 30
Study: 11895821

Group type: EXPERIMENTAL
Intervention: Provision of 10 pairs of Informed Choice leaflets and a training session in their use
Number of subjects: 886
Study: 10465169

Group type: EXPERIMENTAL
Intervention: Oral prednisolone 30 mg once daily for 14 days
Number of subjects: 56

Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 56
Study: 8588170

Group type: EXPERIMENTAL
Intervention: Lift testing before and after a therapeutic trial
Number of subjects: 55

Group type: COMPARATOR
Intervention: Lift testing only at the conclusion of the therapeutic trial
Number of subjects: 55
Study: 8597617

Group type: EXPERIMENTAL
Intervention: e-PTFE (Gore-Tex GTAM) membrane applied to one fenestration
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group (no membrane applied)
Number of subjects: 7